Tegaserod is a 5-HT4 agonist manufactured by Novartis and sold under the names Zelnorm and Zelmac for the management of irritable bowel syndrome and constipation. Approved by the FDA in 2002 it was subsequently removed from the market in 2007 due to FDA concerns about possible adverse cardiovascular effects.
This page contains content from the copyrighted Wikipedia article "Tegaserod"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
